Clinical Trials Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 21, 2017; 23(15): 2763-2770
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2763
Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma
Waled Mohsen, Marcia Rodov, Emilia Prakoso, Barbara Charlton, David G Bowen, David J Koorey, Nicholas A Shackel, Geoffrey W McCaughan, Simone I Strasser
Waled Mohsen, Marcia Rodov, Emilia Prakoso, Barbara Charlton, David G Bowen, David J Koorey, Nicholas A Shackel, Geoffrey W McCaughan, Simone I Strasser, AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney NSW 2050, Australia
Author contributions: Mohsen W analysed data, wrote the paper and completed statistics; Rodov M collected and analysed data and assisted with the manuscript; Prakoso E, Bowen DG, Koorey DJ, Shackel NA and McCaughan GW added clinic patients to the prospective database; Charlton B maintained the prospective database; Strasser SI designed the research study, supervised researchers, obtained ethics approval, set up the database, contributed to the manuscript.
Institutional review board statement: The clinical database and this study were approved by the SLHD Ethics Review Committee (Royal Prince Alfred Zone).
Informed consent statement: Informed consent was given by all participants of the study prior to inclusion.
Conflict-of-interest statement: There are no conflicts of interests recorded for this study.
Data sharing statement: Technical appendix, statistical code, and dataset available from the first author at wmoh6298@uni.sydney.edu.au. Participants gave informed consent for data sharing. No additional data is available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Mohsen Waled, AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital Missenden, Rd Camperdown, Sydney NSW 2050, Australia. wmoh6298@uni.sydney.edu.au
Telephone: +61-4-21967316 Fax: +61-2-95158242
Received: November 8, 2016
Peer-review started: November 8, 2016
First decision: December 19, 2016
Revised: January 8, 2017
Accepted: March 6, 2017
Article in press: March 6, 2017
Published online: April 21, 2017
Processing time: 163 Days and 7.7 Hours
Core Tip

Core tip: In this prospective study of 1078 patients, we examined the relationship between etiology of liver disease with clinical presentation and outcome, following a diagnosis of hepatocellular carcinoma. Our results are clinically useful and relevant for gastroenterologists worldwide. In our diverse and multi-ethnic cohort, patients diagnosed with hepatocellular carcinoma (HCC), who have a background of non-viral liver disease are: (1) Less likely to be participating in an HCC surveillance program; (2) Have more severe liver disease at diagnosis; (3) Have a greater tumor burden at diagnosis; and (4) Less likely to have curative therapies for HCC like liver transplantation or liver resection.